



**IN THE MATTER OF the Patent Act R.S.C. 1985, c. P-4,
as amended**

**AND IN THE MATTER OF Alexion Pharmaceuticals Inc.
and the medicine "Soliris"**

**PANEL ORDER WITH REGARDS TO BIOTECANADA'S SECOND MOTION FOR LEAVE
TO INTERVENE**

Decided by the Hearing Panel on the basis of the written record

1. FURTHER to the motion filed by BIOTECanada on December 20, 2016 for an order granting BIOTECanada further intervener status;
2. FURTHER to Alexion Pharmaceuticals Inc.'s (the "**Respondent**") consent, during the case conference of December 21, 2016, to this motion and agreement to allocate 30 minutes of the time allotted to the Respondent for closing argument to BIOTECanada;
3. AND FURTHER to Board Staff's letter of December 28, 2016, advising that Board Staff does not oppose this motion, with conditions.

THE PANEL ORDERS THAT:

1. BIOTECanada's motion is granted and it is permitted to file written submissions in the form attached as Exhibit A to its Notice of Motion, and to speak for 30 minutes in closing arguments regarding its position and that of its members on this hearing;
2. BIOTECanada will file and serve its written submissions in accordance with sections 10 and 11 of the *Patented Medicine Prices Review Board Rules of Practice and Procedure* by January 20, 2017; and
3. BIOTECanada's 30 minutes of submissions during closing argument shall come out of the time allocated to the Respondent for closing argument.

DATED in Ottawa, this 18th day of January, 2017.

Original signed by

Dr. Mitchell Levine
on behalf of the Panel.